Information Provided By: 
Fly News Breaks for March 27, 2018
FBIO
Mar 27, 2018 | 11:14 EDT
H.C. Wainwright analyst Joseph Pantginis says additional Phase 1b analysis shows Fortress Biotech's CAEL-101 administration improves heart function. Caelum, a Fortress subsidiary, presented a new analysis of data from the Phase 1b trial of CAEL-101 for the treatment of amyloid light chain amyloidosis, the analyst writes in a research note. He believes these data should translate to a positive Phase 3, which he thinks should begin this year. The analyst stays bullish on Fortress Biotech with a Buy rating and $11 price target.
News For FBIO From the Last 2 Days
There are no results for your query FBIO
